Suggested remit: To appraise the clinical and cost effectiveness of vosoritide within its marketing authorisation for treating achondroplasia in children and young people under 18 years.
 
Status Awaiting development
Decision None selected
Process TA
ID number 3807

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
30 October 2024 Vosoritide for treating achondroplasia in children and young people under 18 years has now been combined as one appraisal. The ID number to be used for this combined appraisal is ID6488
24 November 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of vosoritide for treating achondroplasia in children and young people under 18 years. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. Following an update from the company that is developing vosoritide, NICE has agreed that holding a scoping exercise at this time is not appropriate. As a consequence of this, the consultation on the draft scope has closed and the workshop arranged for Monday 07 December 2020 has been cancelled. Please accept our apologies for any inconvenience. The scoping exercise will be rescheduled to take place at a later date. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on emily.richards@nice.org.uk)

For further information on our processes and methods, please see our CHTE processes and methods manual